SCHEMBL4714352

SCHEMBL4714352

Fc1ccccc1/C=C/c1ccccn1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 10/20 0.64
NPC1 O15118 3/20 0.64
RAB9A P51151 3/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
ATM Q13315 1/20 0.64
GRM4 Q14833 1/20 0.60
PKM P14618 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 2/20 0.51
HTR2A P28223 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714353 1.00 NFE2L2 (0.64) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL30379533 1.00 NFE2L2 (0.64) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL28801342 0.94 NFE2L2 (0.57) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL229328 0.80 NPC1 (1.00) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL31560044 0.80 NPC1 (1.00) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL2234105 0.80 NFE2L2 (1.00) NFE2L2NPC1RAB9AGRM4PKM
SCHEMBL9394256 0.80 NPC1 (1.00) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL229329 0.80 NPC1 (1.00) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL709991 0.79 NPC1 (0.57) NFE2L2NPC1RAB9AMEN1KMT2A
SCHEMBL708946 0.76 NPC1 (0.64) NFE2L2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116120224-A Synthesis method of chiral beta-aza-arene tertiary carbon center compound 河南工业大学 2023-05-16 CN disclosed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed